VC firm blog
Everything we hold that OneVentures portfolio published.
Every article we hold from OneVentures portfolio.
Publisher post sharing its healthcare partner's profile in the business press, plus coverage of a biotech firm's $1.6b takeover, a vaccine company naming a new CEO, and a software firm being acquired.
Under OneVentures portfolio ·leads this story in the feed
A OneVentures post announcing the sale of digital health group Eucalyptus to an unnamed New York stock exchange-listed healthcare company for 1.6 billion dollars, set against pharmaceutical appetite for local biotech facing patent expiries.
A fund's insights listing: its headline flags Vaxxas naming an ex-Merck vaccines chief as CEO, while linked teasers report Eucalyptus' $1.6b sale and Accel-KKR's takeover of Phocas.
Curated OneVentures roundup: Eucalyptus sold to a New York-listed healthcare group for $1.6 billion and Vaxxas named ex-Merck vaccines president David Peacock as CEO, plus patent-cliff and women-in-tech links.
A OneVentures blog post flags an artificial heart developer it has backed as out soliciting fresh capital; the text provided names no company, investors, or completed round.
A OneVentures blog stub links to Capital Brief's report that the venture firm is approaching a major growth milestone, has added key staff, and is preparing a fresh fund.
OneVentures' insights feed highlights a pharma patent-cliff analysis, an AFR feature, Eucalyptus' $1.6b sale to a US healthcare group, and Vaxxas naming David Peacock chief executive.
The venture firm's own post says it is out raising for a new vehicle to fill space corporate investors have vacated; the text states no close and no committed amount.
OneVentures' media-roundup page archives press coverage of the firm and of Employment Hero's major funding round, while its headline funds-under-management milestone remains an intention rather than a completed close.
A OneVentures blog post linking to Sky News coverage of an Australian engineer's artificial heart invention, plus a related item on US regulatory clearance for BiVACOR's heart device human trial.
OneVentures insights listing linking to coverage of Eucalyptus's $1.6b sale to a US-listed healthcare company and Vaxxas hiring a former Merck vaccines president as CEO.
Publisher's post about a venture firm multiplying its money thirteen-fold on one startup bet; the page also carries linked reports of Eucalyptus's $1.6 billion sale and Vaxxas naming David Peacock chief executive.
US regulators cleared first-in-human testing of BiVACOR's total artificial heart; the OneVentures page also links earlier coverage and the Biomedical Translation Fund's investment in the device.
A OneVentures post announcing Employment Hero's $263 million raise, billed as the year's largest, linking out to the Financial Review for the full story.
Under OneVentures portfolio ·leads this story in the feed
OneVentures' insights page rounds up media coverage: an AFR report on Employment Hero's $263 million raise, a Forbes piece on OneVentures reaching $1 billion under management, and two AFR features on venture funding.
OneVentures links out to Vaxxas's announcement that the biotech has opened a manufacturing site for its needle-free vaccine patch.
OneVentures' blog links to an Australian Financial Review report saying biotech ImmVirX has secured a raise at a $75 million valuation; the post itself gives no amount, investors, or dates.
Also SmartCompany·Techboard
OneVentures' blog post pointing readers to Financial Review coverage of the firm and the artificial-heart developer BiVACOR; the post itself contains no deal details.
A OneVentures post reports a needle-free vaccine developer raising A$34 million; linked items on the page note Eucalyptus's $1.6 billion sale to a US-listed healthcare firm and Vaxxas naming David Peacock chief executive.
Also Blackbird Ventures portfolio·Startup Daily·SmartCompany·Dealroom·SmartCompany·Startup Daily·Dealroom·Forbes Australia
Under Brandon BioCatalyst portfolio ·leads this story in the feed
OneVentures publishes an interview with Edrolo co-founder and co-CEO Ben Sze, discussing the education company. No funding, exit, hire or cohort details are stated in the available text.
OneVentures announces it led Kepler Analytics' AU$22 million Series A, describing the Melbourne retail analytics firm's sensor technology, customer base, growth and expansion plans.
Under Shearwater Capital portfolio ·leads this story in the feed
Deals recorded from OneVentures portfolio's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| Employment Hero | Unnamed stage | 19 Oct 2023 | $263m | |
| ImmVirX | undisclosed | Jun 2023 | $15m | |
| Vaxxas | Unnamed stage | 9 Dec 2022 | $34m | |
| Kepler Analytics | Series B | 23 Feb 2022 | $22m |
Companies named in OneVentures portfolio's articles, most-covered first.
| Company | What it does | Articles |
|---|---|---|
| Accel-KKR | 2 | |
| Aēsop | 1 | |
| Biomedical Translation Fund | 1 | |
| BiVACOR | 3 | |
| Edrolo | 1 | |
| Employment Hero | Another Australian company backed by TCV | 3 |
| Eucalyptus | 8 | |
| FDA | US Food and Drug Administration | 1 |
| Hanes Group | 1 | |
| Hudsons Bay | 1 | |
| ImmVirX | biotech startup | 1 |
| Kepler Analytics | 1 | |
| Merck | 7 | |
| Officeworks | 1 | |
| Pandora | 1 | |
| Phocas | Mature scaleup, outlier among 10-year-plus startups for funding raised | 2 |
| Vaxxas | Biotech/MedTech company | 8 |
Investors named in OneVentures portfolio's articles, most-covered first.
| Investor | What it does | Articles |
|---|---|---|
| OneVentures | 12 |